Patents by Inventor George N. Cox, III
George N. Cox, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9637530Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.Type: GrantFiled: April 25, 2014Date of Patent: May 2, 2017Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III
-
Publication number: 20160200790Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.Type: ApplicationFiled: April 25, 2014Publication date: July 14, 2016Applicant: BOLDER BIOTECHNOLOGY, INC.Inventor: George N. Cox, III
-
Patent number: 8748392Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.Type: GrantFiled: February 2, 2012Date of Patent: June 10, 2014Assignee: Bolder BioTechnology Inc.Inventor: George N. Cox, III
-
Patent number: 8329866Abstract: Disclosed are polymer sFlt-1 conjugates, variants of sFlt-1, compositions comprising such conjugates and variants, including cysteine variants of sFlt-1. Also disclosed is the use of such conjugates, variants and compositions in methods to inhibit the activity of VEGF, to inhibit angiogenesis, and to treat or reduce at least one symptom of diseases and conditions in which it is desirable to inhibit VEGF activity and/or angiogenesis.Type: GrantFiled: October 3, 2006Date of Patent: December 11, 2012Assignee: Bolder Biotechnology, Inc.Inventors: Mary S. Rosendahl, George N. Cox, III
-
Publication number: 20120276042Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: ApplicationFiled: June 15, 2011Publication date: November 1, 2012Inventor: George N. Cox, III
-
Publication number: 20120231040Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.Type: ApplicationFiled: February 2, 2012Publication date: September 13, 2012Applicant: BOLDER BIOTECHNOLOGY, INC.Inventor: George N. Cox, III
-
Patent number: 8148500Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: GrantFiled: September 21, 2010Date of Patent: April 3, 2012Assignee: Bolder BioTechnology, Inc.Inventors: George N. Cox, III, Daniel H. Doherty
-
Patent number: 8133480Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.Type: GrantFiled: February 24, 2009Date of Patent: March 13, 2012Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III
-
Publication number: 20110250169Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: ApplicationFiled: May 13, 2011Publication date: October 13, 2011Inventor: George N. Cox, III
-
Publication number: 20110172151Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: ApplicationFiled: September 21, 2010Publication date: July 14, 2011Applicant: BOLDER BIOTECHNOLOGY, INC.Inventors: George N. Cox, III, Daniel H. Doherty
-
Patent number: 7964184Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: GrantFiled: October 30, 2007Date of Patent: June 21, 2011Inventor: George N. Cox, III
-
Patent number: 7959909Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: GrantFiled: October 30, 2007Date of Patent: June 14, 2011Assignee: Bolder BioTechnology, Inc.Inventor: George N. Cox, III
-
Patent number: 7947655Abstract: The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.Type: GrantFiled: October 22, 2009Date of Patent: May 24, 2011Assignee: Bolder Biotechnology, Inc.Inventors: George N. Cox, III, Daniel H. Doherty, Mary S. Rosendahl
-
Publication number: 20100285014Abstract: The present invention relates to novel methods for making fusion proteins comprising a cytokine or growth factor fused to an immunoglobulin domain. The growth factor/cytokine can be fused directly to an immunoglobulin domain or through a peptide linker. The purified growth factor/cytokine-IgG fusion proteins produced by the novel methods are biologically active and can be used to treat diseases for which the non-fused growth factor/cytokine are useful.Type: ApplicationFiled: May 10, 2010Publication date: November 11, 2010Applicant: BOLDER BIOTECHNOLOGY, INC.Inventors: George N. Cox, III, Daniel H. Doherty
-
Patent number: 7824669Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: GrantFiled: July 14, 2009Date of Patent: November 2, 2010Assignee: Bolder Biotechnology, Inc.Inventors: George N. Cox, III, Daniel H. Doherty
-
Publication number: 20100266529Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: ApplicationFiled: November 2, 2009Publication date: October 21, 2010Applicant: BOLDER BIOTECHNOLOGY, INC.Inventor: George N. Cox, III
-
Patent number: 7795396Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: GrantFiled: March 2, 2005Date of Patent: September 14, 2010Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III
-
Patent number: 7788044Abstract: The invention provides criteria and methods for selecting optimum subsequence(s) from a target gene for targeting by a zinc finger protein. Some of the methods of target site selection seek to identify one or more target segments having a DNA motif containing one or more so-called D-able subsites having the sequence 5?NNGK3?. Other methods of the invention are directed to selection of target segments within target genes using a correspondence regime between different triplets of three bases and the three possible positions of a triplet within a nine-base site. In another aspect, the invention provides methods of designing zinc finger proteins that bind to a preselected target site. These methods can be used following the preselection of target sites according to the procedures and criteria described above. The methods of design use a database containing information about previously characterized zinc finger proteins.Type: GrantFiled: February 12, 2007Date of Patent: August 31, 2010Assignee: Sangamo Biosciences, Inc.Inventors: Stephen P. Eisenberg, Casey C. Case, George N. Cox, III, Andrew Jamieson, Edward J. Rebar
-
Patent number: 7754855Abstract: The present invention relates to novel methods for making fusion proteins comprising a cytokine or growth factor fused to an immunoglobulin domain. The growth factor/cytokine can be fused directly to an immunoglobulin domain or through a peptide linker. The purified growth factor/cytokine-IgG fusion proteins produced by the novel methods are biologically active and can be used to treat diseases for which the non-fused growth factor/cytokine are useful.Type: GrantFiled: July 13, 2000Date of Patent: July 13, 2010Assignee: Bolder Biotechnology, Inc.Inventors: George N. Cox, III, Daniel H. Doherty
-
Patent number: 7732572Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: GrantFiled: June 10, 2004Date of Patent: June 8, 2010Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III